| Date | Title | Description |
| 23.08.2011 | Venture Financing for MI Firms Down More Than 41 Percent | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture capital investment in Michigan-based startups is down 41 percent this year compared to 2010, according to a report released yesterday by the Michigan Venture Capital A... |
| 22.10.2010 | Cerenis Therapeutics adds $13.9M for plaque-reversing heart drug | The company has several cholesterol-related drugs in its pipeline. But its lead candidate, CER-001, mimics high-density lipid (“good”) cholesterol and can rapidly reverse atherosclerotic plaque, which causes heart disease.
Cerenis will use ... |
| 21.10.2010 | Cerenis Therapeutics Raises Further €10M in Second Close of Series C Financing | Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL (“good” cholesterol) to treat cardiovascular and other metabolic diseases, has raised a further €10m in a second ... |
| 26.07.2010 | Cerenis Therapeutics Raises €40M | Cerenis Therapeutics SA, a Toulouse, France and Ann Arbor, USA-based biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of High-density lipoprotein (HDL or “good cholesterol”) t... |
| 26.07.2010 | Cerenis Therapeutics gets $51M Series C for cardiovascular disease drug | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| - | Publication of the LOCATION clinical study results in the renowned scientific journal of the European Atherosclerosis Society (EAS) | Results of the LOCATION study demonstrate the functionality of CER-001
and are reassuring prior to the publication of the study CARAT, planned for first quarter of 2017
Toulouse, FRANCE, Ann Arbor, UNITED STATES, June 2, 2016 – Cerenis Th... |
| - | Cash position and update on clinical developments for Q1 2017 | Toulouse, FRANCE, Ann Arbor, UNITED-STATES, April 20, 2017, 6:30pm – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of innovative therapi... |
| - | First patient enters Phase III TANGO clinical trial to evaluate efficacy to regress atherosclerosis and safety of CER-001 in patients with Familial Primary HypoAlphalipoproteinemia (FPHA) | Press Release
First patient enters Phase III TANGO clinical trial to evaluate efficacy to regress atherosclerosis and safety of CER-001 in patients with Familial Primary HypoAlphalipoproteinemia (FPHA)
• A trial headed by Prof. Erik Stroe... |
| - | 2018 Half-Year Results | Solid cash position of €13.5 million
and significant scientific advances
Key highlights in the first half-year of 2018: primary objective met in the first results of TARGET PHASE II study, strategic partnership with the University of ... |
| - | 2017 ANNUAL RESULTS AND UPDATE ON TANGO | • Solid cash position of €16.3 million at December 31, 2017
• TANGO timing update: results postponed, full 12 month results expected in Q4
2018 per protocol
• Progression in the clinical developments of CER-209 in NASH and NAFLD
• Exten... |
| - | Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH | Toulouse, FRANCE, Ann Arbor, UNITED-STATES, June 7, 2017, 07:00 pm cet – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of innovative lip... |
| - | Cerenis Therapeutics Announces Last Patient Dosed in CARAT Phase II Study with CER-001 in Post-Acute Coronary Syndrome Patients | Topline data to be announced no later than the first quarter of 2017
TOULOUSE, France and ANN ARBOR, United States, November 8, 2016 – Cerenis Therapeutics (Euronext: CEREN- ISIN: FR0012616852), an international biopharmaceutical company d... |
| - | Cash position and activity update for Q4 2017 | • Solid cash position of €16.3 million at December 31, 2017
• Acquisition of LYPRO Biosciences to build the first HDL-based targeted drug
delivery platform, dedicated to the immune-oncology and chemotherapy market
• First patients enter ... |
| - | Cerenis Therapeutics featured prominently at the INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS (IAS) | Experimental results demonstrate dose-dependent inhibition of atherosclerotic plaque formation for CER-001 as a novel engineered HDL-mimetic and active role to treat atherosclerosis and non-alcoholic steatohepatitis (NASH) for CER-209 as an... |
| - | New Data for CER-001 presented in key Oral Session at AMERICAN HEART ASSOCIATION (AHA) CONFERENCE 2015 | Data show that CER-001 at 3 mg/kg dose induced atherosclerosis regression as illustrated by a statistically significant decrease in plaque burden, a marker directly linked to the risk of cardiovascular outcomes
Professor Stephen Nicholls, ... |
| - | Cerenis Therapeutics announces new Board members | Toulouse, FRANCE, Ann Arbor, UNITED STATES, June 9, 2015 – Cerenis Therapeutics (FR0012616852- CEREN), an
international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies
(“good cholesterol”) ... |
| - | First patients enter TARGET study, recently initiated by Cerenis Therapeutics to evaluate HDL nanoparticles in patients with esophageal cancer | Toulouse, FRANCE, Lakeland, UNITED STATES, November 22, 2017, 8.00 am CET – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible) an international biopharmaceutical company dedicated to the discovery and development of HDL-based in... |
| - | 2017 Half-Year Results | Solid cash position of €20 million
and significant scientific progress
Toulouse, FRANCE, Lakeland, UNITED STATES, September 12, 2017 – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible) an international biopharmaceutical compa... |
| - | Cerenis Therapeutics announces its results for the first half of 2015. | Toulouse, FRANCE and Ann Arbor, UNITED STATES, August 25, 2015 – Cerenis Therapeutics (FR0012616852- CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholestero... |
| - | Cash position and revenue for 2015 | Significant clinical achievements in 2015 Strengthening of the patent strategy
Toulouse, FRANCE, Ann Arbor, UNITED STATES, February 16, 2016 – Cerenis Therapeutics (FR0012616852- CEREN), an international biopharmaceutical company dedicated... |
| - | CERENIS THERAPEUTICS announces the appointment of a new Chief Medical Officer and new Board Members | – Dr. Renee Benghozi to become Chief Medical Officer (CMO)
– Mr. Christian Chavy, Drs. Michael Davidson and Marc Riviere to join the Board of Directors
– Dr. Stephen Nicholls appointed Principal investigator and Chairman of the Steering C... |
| - | Clinical progress, cash position and revenue for Q4 2016 | Toulouse, FRANCE, Ann Arbor, UNITED STATES, January 19, 2017 – Cerenis Therapeutics (FR0012616852 – CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol... |
| - | CERENIS announces the results of TANGO, a Phase III clinical study evaluating CER-001 in patients with HDL deficiency | Missed primary endpoint in the TANGO Phase III study, there was no statistically significant difference between the placebo and CER-001 treated groups for the primary outcome
The safety and tolerability profile was favorable and consis... |
| - | Cerenis Therapeutics gets $51M Series C for cardiovascular disease drug | Cerenis Therapeutics has pulled in a $51.7 million Series C round to fund Phase 2 trials of a drug that treats cardiovascular disease.
The company, with operations in France and Ann Arbor, Michigan, has now raised $138 million in venture fu... |
| - | Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 | TOULOUSE, France and ANN ARBOR, Michigan, 2 January 2014 – Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression?) study did no... |
| - | Cerenis Therapeutics announces the publication of positive preclinical data in the world-renowned scientific journal PLOS ONE | • CER-001 mimics native HDL
• Ability of CER-001 to inhibit the formation of atherosclerotic plaque with better efficacy at lower doses
• Confirmation of the optimal design of the Phase II CARAT clinical trial in the post Acute Coronary S... |
| - | Cerenis Therapeutics is joining the Euronext indexes CAC® Small, CAC® Mid & Small and CAC® All-Tradable | Toulouse, FRANCE, Ann Arbor, UNITED STATES, September 17, 2015 – Cerenis Therapeutics (FR0012616852 – CEREN
– Eligible PEA-PME), an international biopharmaceutical company dedicated to the discovery and development of
innovative HDL thera... |
| - | Cash position and activity update for Q3 2017 | • Solid cash position of €18.3 million at September 30, 2017
• CER-001: completion of patient enrollment in the Phase III study, TANGO, in HDL genetic deficiency
• CER-209: positive results from Phase I Single Dose Tolerance study for NAF... |
| - | Cerenis Therapeutics adds $13.9M for plaque-reversing heart drug | Ann Arbor, Michigan, biopharmaceutical company Cerenis Therapeutics added $13.9 million to a July investment round that it will use to continue clinical trials of a drug to treat heart disease.
Co-based in Toulouse, France, Cerenis closed a... |
| - | 2015 annual results | Strong cash position of €43 million and excellent clinical progress
Toulouse, FRANCE, Ann Arbor, UNITED-STATES, March 1, 2016 – Cerenis Therapeutics (FR0012616852 – CEREN), an international biopharmaceutical company dedicated to the discov... |
| - | Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology (ESC) Congress 2016 | Professor Alberto Corsini, Department of Pharmacology and Biomolecular Sciences, University of Milan, Italy, presented CER-001 data at ESC
Toulouse, FRANCE, Ann Arbor, UNITED STATES, September 1 2016 – Cerenis Therapeutics (FR0012616852 – ... |
| - | Cerenis Therapeutics announces the publication of an initiation of coverage report by PORTZAMPARC, within the framework of the share’s market coverage | Buy recommendation with a target price of 18.8 euros per share*
Toulouse, FRANCE, Ann Arbor, UNITED-STATES, April 18, 2016 – Cerenis Therapeutics (FR0012616852 – CEREN), an international biopharmaceutical company dedicated to the discovery... |
| - | Completion of patient enrolment in the CARAT study – meeting the clinical schedule | Toulouse, FRANCE, Ann Arbor, UNITED STATES, August 30, 2016 – Cerenis Therapeutics (FR0012616852 –
CEREN), an international biopharmaceutical company dedicated to the discovery and development of
innovative HDL therapies (“good cholestero... |
| - | 2016 ANNUAL RESULTS | Solid cash position of €24.7 million and finalization of CARAT phase 2 clinical study
Toulouse, France, Ann Arbor, United States, February 17 2017 – 6 pm CET – Cerenis Therapeutics (FR0012616852- CEREN), an international biopharmaceutical ... |
| - | Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD | Presentation of CER-209 at the 2nd annual H.C. Wainwright NASH Investor Conference on March 19, 2018
• Regulatory authority approval to begin enrollment in the study
• Daily administration of increasing doses of CER-209 over a 28-day peri... |
| - | Cerenis Therapeutics announces the results of the LOCATION study | The LOCATION study demonstrates the functionality of CER-001 in increasing cholesterol efflux
capacity and targeting plaques in patients with advanced atherosclerotic disease
Toulouse, FRANCE, Ann Arbor, UNITED STATES, July 15, 2015 – Cer... |
| - | CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery | • Combining LYPRO Biosciences’ NanoDisk® technology with CERENIS’ HDL solution to build the first HDL nanoparticle delivery platform to be initially dedicated to the oncology market
• Using its existing technologies with LYPRO’s NanoDisk® ... |
| - | Cerenis receives EMA Orphan Drug Designation for CER-001 for the treatment of APoA-I and ABCA-1 deficiencies | TOULOUSE, France and ANN ARBOR, Michigan, USA, 3 September 2014 – Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular diseas... |
| - | CER-001: Analysis of clinical results to be presented at the American Heart Association Scientific Congress, on November 9, 2015 in Orlando, UNITED-STATES | Toulouse, FRANCE, Ann Arbor, UNITED STATES, November 3, 2015 – Cerenis Therapeutics (FR0012616852 – CEREN – Eligible PEA-PME), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies... |
| - | First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients | • CER-001 is a novel HDL-mimetic designed to mimic the beneficial properties of natural nascent HDL (HDL pre-β)
• A trial headed by Professor Stephen Nicholls, Director of the prestigious Heart Health Research team at SAHMRI (South Austral... |
| - | Cash position and revenue for Q3 2015 | Toulouse, FRANCE, Ann Arbor, UNITED-STATES, November 12, 2015 – Cerenis Therapeutics (FR0012616852-
CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL
therapies (“good cholester... |